» Articles » PMID: 38463811

A PANoptosis Pattern to Predict Prognosis and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Mar 11
PMID 38463811
Authors
Affiliations
Soon will be listed here.
Abstract

Individuals diagnosed with head and neck squamous cell carcinoma (HNSCC) experience a significant occurrence rate and are susceptible to premature spreading, resulting in a bleak outlook. Therapeutic approaches, such as chemotherapy, targeted therapy, and immunotherapy, may exhibit primary and acquired resistance during the advanced phases of HNSCC. There is currently no viable solution to tackle this issue. PANoptosis-a type of non-apoptotic cell death-is a recently identified mechanism of cellular demise that entails communication and synchronization among thermal apoptosis, apoptosis, and necrosis mechanisms. However, the extent to which PANoptosis-associated genes (PRG) contribute to the forecast and immune reaction of HNSCC remains mostly undisclosed. The present study aimed to thoroughly analyze the potential importance of PRG in HNSCC and report our discoveries. We systematically analyzed 19 PRG from previous studies and clinical data from HNSCC patients to establish a PAN-related signature and assess its prognostic, predictive potential. Afterward, the patient information was separated into two gene patterns that corresponded to each other, and the analysis focused on the connection between patient prognosis, immune status, and cancer immunotherapy. The PAN score was found to correlate with survival rates, immune systems, and cancer-related pathways. We then validated the malignant role of CD27 among them in HNSCC. In summary, we demonstrated the effectiveness of PAN.Score-based molecular clustering and prognostic features in predicting the outcome of HNSCC. The discovery we made could enhance our comprehension of the significance of PAN.Score in HNSCC and facilitate the development of more effective treatment approaches.

Citing Articles

Combination of bulk RNA and single-cell sequencing unveils PANoptosis-related immunological ecology hallmarks and classification for clinical decision-making in hepatocellular carcinoma.

Liu L, Zhou Z, Xie C, Hu L Sci Rep. 2024; 14(1):22517.

PMID: 39342037 PMC: 11438900. DOI: 10.1038/s41598-024-73847-1.


Identification of PANoptosis-related biomarkers and analysis of prognostic values in head and neck squamous cell carcinoma.

Yang P, Huang G, Li Y, Yu L, Yin Z, Li Q Sci Rep. 2024; 14(1):9824.

PMID: 38684755 PMC: 11058810. DOI: 10.1038/s41598-024-60441-8.

References
1.
Pan H, Pan J, Li P, Gao J . Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer. Clin Immunol. 2022; 238:109019. DOI: 10.1016/j.clim.2022.109019. View

2.
Zhu Z, Ying Z, Zeng M, Zhang Q, Liao G, Liang Y . Trichosanthin cooperates with Granzyme B to restrain tumor formation in tongue squamous cell carcinoma. BMC Complement Med Ther. 2021; 21(1):88. PMC: 7944607. DOI: 10.1186/s12906-021-03266-6. View

3.
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

4.
Pang K, Shi Z, Wei L, Dong Y, Ma Y, Wang W . Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug Resist Updat. 2022; 66:100907. DOI: 10.1016/j.drup.2022.100907. View

5.
Wang X, Sun R, Chan S, Meng L, Xu Y, Zuo X . PANoptosis-based molecular clustering and prognostic signature predicts patient survival and immune landscape in colon cancer. Front Genet. 2022; 13:955355. PMC: 9515384. DOI: 10.3389/fgene.2022.955355. View